Wolfe Research Initiates Coverage On Madrigal Pharmaceuticals with Outperform Rating
Portfolio Pulse from Benzinga Newsdesk
Wolfe Research has initiated coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with an Outperform rating, as per analyst Andy Chen.
June 11, 2024 | 6:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wolfe Research has initiated coverage on Madrigal Pharmaceuticals with an Outperform rating, indicating a positive outlook for the stock.
An Outperform rating from a reputable firm like Wolfe Research typically suggests a positive short-term impact on the stock price as it indicates confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100